Loading
A phase 3 trial of Durvalumab in bladder & urothelial cancer, run by AstraZeneca, active and no longer recruiting.
BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants is a phase 3 interventional study registered as NCT05943106 by AstraZeneca, with 100 participants enrolled, started 2023-08-11 and due to reach its primary completion in 2025-06-16. Interventions recorded: Durvalumab and BCG.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Parexel, AstraZeneca and the tag pipeline.
Shares Durvalumab, AstraZeneca, Bladder & urothelial cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Durvalumab, AstraZeneca, Bladder & urothelial cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Durvalumab, AstraZeneca, Immune checkpoint inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/